Minerva Neurosciences to Present at Jefferies Virtual Healthcare Conference
Minerva Neurosciences, a clinical-stage biopharmaceutical company focused on CNS disorders, will participate in the Jefferies Virtual Healthcare Conference on June 2, 2021, at 11:00 a.m. ET. The event will be accessible through a live and archived webcast on the company's investor relations website. Minerva's portfolio includes roluperidone (MIN-101), in clinical trials for schizophrenia, and MIN-301, in pre-clinical development for Parkinson's disease. The stock is listed on NASDAQ under the symbol NERV.
- None.
- None.
WALTHAM, Mass., May 28, 2021 (GLOBE NEWSWIRE) -- Minerva Neurosciences, Inc. (NASDAQ: NERV), a clinical-stage biopharmaceutical company focused on the development of innovative therapies to treat central nervous system (CNS) disorders, today announced that it will participate in the Jefferies Virtual Healthcare Conference on June 2, 2021 at 11:00 a.m. Eastern Time.
The presentation will be webcast and accessible on a live and archived basis through the investor relations section of the Company’s web site, http://ir.minervaneurosciences.com.
About Minerva Neurosciences
Minerva’s portfolio of compounds includes: roluperidone (MIN-101), in clinical development for schizophrenia, and MIN-301, in pre-clinical development for Parkinson’s disease. Minerva’s common stock is listed on the NASDAQ Global Market under the symbol “NERV.” For more information, please visit www.minervaneurosciences.com.
Contact:
William B. Boni
VP, Investor Relations/
Corp. Communications
Minerva Neurosciences, Inc.
(617) 600-7376
FAQ
What event will Minerva Neurosciences be participating in?
What time is Minerva's presentation at the Jefferies Virtual Healthcare Conference?
How can I access Minerva's presentation at the conference?
What are the main products in Minerva's portfolio?
Under what symbol is Minerva Neurosciences listed on NASDAQ?
